Women are and will be the predominant users of GLP-1 users, but research gaps remain critical

The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28—Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women. The authors, that include Professor Paul Franks, Lund University, Helsingborg Hospital, Helsingborg, Sweden and Professor Claire Meek, Leicester Diabetes Research Centre and Leicester NIHR Biomedical Research Centre, Leicester, UK and colleagues, issue a call to action to improve the evidence based across the board for GLP-1 RA use in women worldwide.

Read it at Medical Xpress ↗

← Front page